The Court of Justice of the European Union (CJEU) dismissed the appeals lodged by generic manufacturers who had entered into ‘pay for delay’ agreements with the pharmaceutical group Servier aimed at delaying the entry onto the EU market of generics competing with perindopril, a medicine used to treat certain heart diseases, in a ruling handed down on Thursday 27 June (joined cases C-144/19, C-151/19, C-166/19, C-176/19, C-197/19, C-198/19 and C-201/19).
Generic manufacturers Lupin, Niche...